A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.

Trial Profile

A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2017

At a glance

  • Drugs Mirabegron (Primary) ; Mirabegron/solifenacin (Primary) ; Solifenacin (Primary)
  • Indications Overactive bladder
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SYMPHONY
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 15 Apr 2014 Results assessing cardiovascular safety presented at the 29th Congress of the European Association of Urology.
    • 30 Aug 2013 Results presented at the 43rd Annual Meeting of the International Continence Society.
    • 08 May 2013 Results presented at the 108th Annual Meeting of the American Urological Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top